Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 4/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 3/20 | 0.32 |
| ▸ | CDK8 | P49336 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784977 | 1.00 | KMT2A (0.37) | KMT2AEPHX2TYRO3MERTKKDM5A | |
| SCHEMBL3790727 | 0.90 | EPHX2 (0.38) | EPHX2TYRO3MERTKKDM5ARIPK1 | |
| SCHEMBL3790725 | 0.90 | EPHX2 (0.38) | EPHX2TYRO3MERTKKDM5ARIPK1 | |
| SCHEMBL7500241 | 0.89 | TYRO3 (0.38) | EPHX2TYRO3MERTKKDM5ARIPK1 | |
| SCHEMBL3683862 | 0.89 | TYRO3 (0.38) | EPHX2TYRO3MERTKKDM5ARIPK1 | |
| SCHEMBL13228548 | 0.89 | EPHX2 (0.34) | EPHX2TYRO3MERTKRIPK1CCNC | |
| SCHEMBL3792581 | 0.89 | EPHX2 (0.34) | EPHX2TYRO3MERTKRIPK1CCNC | |
| SCHEMBL7496017 | 0.89 | KDM5B (0.41) | EPHX2KDM5A | |
| SCHEMBL3699901 | 0.89 | KDM5B (0.41) | EPHX2KDM5A | |
| SCHEMBL3787876 | 0.87 | TEAD1 (0.41) | EPHX2TYRO3MERTKMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | KMT2A 3145/4885EPHX2 1834/4885TYRO3 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.